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Abstract: Glutathione is abundant in the lining fluid that bathes the gas exchange surface of the lung. On the one hand 
glutathione in this extracellular pool functions in antioxidant defense to protect cells and proteins in the alveolar space 
from oxidant injury; on the other hand, it functions as a source of cysteine to maintain cellular glutathione and protein 
synthesis. These seemingly opposing functions are regulated through metabolism by gamma-glutamyl transferase (GGT, 
EC 2.3.2.2). Even under normal physiologic conditions, lung lining fluid (LLF) contains a concentrated pool of GGT 
activity exceeding that of whole lung by about 7-fold and indicating increased turnover of glutathione at the epithelial 
surface of the lung. With oxidant stress LLF GGT activity is amplified even further as glutathione turnover is accelerated 
to meet the increased demands of cells for cysteine. Mouse models of GGT deficiency confirmed this biological role of 
LLF GGT activity and revealed the robust expansiveness and antioxidant capacity of the LLF glutathione pool in the 
absence of metabolism. Acivicin, an irreversible inhibitor of GGT, can be utilized to augment LLF fluid glutathione 
content in normal mice and novel GGT inhibitors have now been defined that provide advantages over acivicin. Inhibiting 
LLF GGT activity is a novel strategy to selectively augment the extracellular LLF glutathione pool. The enhanced 
antioxidant capacity can maintain lung epithelial cell integrity and barrier function under oxidant stress.  
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LUNG LINING FLUID (LLF) 
Recent research using mouse models susceptible to 
oxidant stress supports a cause and effect relationship 
between antioxidant defense and susceptibility to lung injury 
[1]. These studies, together with others on acute 
inflammatory lung disease [2, 3] have renewed interest in 
glutathione homeostasis as an antioxidant defense 
mechanism within the lung. The lung is lined by a 
continuous, thin layer of fluid (lung lining fluid, LLF) that 
bathes the entire epithelial surface. LLF functions at the air-
liquid interface as an aqueous medium for exchange of 
molecules within the surfactant system, a supportive medium 
for the alveolar macrophage, a protective surface for the thin 
alveolar septum, and a component of the air-blood diffusion 
distance [4]. In its protective function LLF shields cells 
against oxidants, which may be inhaled from the 
environment or generated endogenously by inflammatory 
cells. Glutathione is one of the small antioxidant molecules 
within LLF. Although some argue that it is not the most 
abundant of these antioxidants, LLF glutathione has been the 
focus of much attention for at least two reasons: its 
concentration exceeds that of blood by over 100-fold, and its 
major form is the antioxidant glutathione (GSH), as opposed 
to glutathione disulfide (GSSG) [5]. Glutathione is a 
versatile antioxidant within the LLF where it also coats the 
entire lung surface [6]. It directly buffers the hypohalous 
acids, very potent and potentially injurious oxidants 
produced by inflammatory cells [7] and with inhalation of 
chlorine gas [8]. It limits the accumulation of hydrogen 
peroxides and lipid peroxides indirectly by functioning as a 
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cofactor for extracellular glutathione peroxidase [9]. 
Glutathione also maintains the bioavailability of small 
antioxidant molecules, such as nitric oxide [10], ascorbic 
acid [11], and alpha-tocopherol [12]. More recently, 
glutathione and glutathione disulfide have been shown to 
exhibit an added antioxidant activity by their ability to 
complex with metals, such as Fe
II and Cu
I  [13]. Recent 
reviews have detailed the role of lung glutathione production 
in inflammation and lung disease [14, 15]. Our review will 
focus on the role of the LLF glutathione pool in antioxidant 
defense at the lung epithelial surface. Herein we will discuss 
a strategy to augment LLF glutathione content by inhibiting 
LLF glutathione metabolism.  
AUGMENTING LLF GLUTATHIONE 
While determinants of the exact size of the LLF 
glutathione pool are not fully understood, augmentation of 
LLF glutathione has been shown to protect against oxidant-
mediated injury [15]. LLF glutathione content has been 
correlated with susceptibility to and severity of several lung 
diseases. In asthmatics, where increased oxidant burden is 
present in the airways due to inflammation, higher levels of 
LLF glutathione correlate with lower levels of airway hyper-
responsiveness in humans [16] and in a mouse model of 
cytokine-driven allergic airway inflammation [3]. LLF 
glutathione is increased in smokers with COPD compared to 
non-smokers [5], but this rise is still less than that of smokers 
without COPD, suggesting that sufficient augmentation of 
this pool protects against COPD [17]. In the acute respiratory 
distress syndrome (ARDS), LLF glutathione deficiency in 
hospitalized alcoholics has been directly linked with 
increased incidence and severity of lung injury [18]. 
Replacement of this deficit can alleviate this risk [19, 20], a 
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oxidizing events in LLF directly link with acute lung injury 
pathogenesis [2]. LLF glutathione deficits are also present in 
idiopathic pulmonary fibrosis (IPF) [21], HIV disease [22] 
and cystic fibrosis [23]. In fact, increases in the LLF 
glutathione pool may account for some of the protective 
effects of hypertonic saline in cystic fibrosis [24]. All 
together, these observations support a role for LLF 
glutathione in protection against cell injury and lung disease. 
Hence continued assessment of LLF glutathione content and 
development of new strategies to augment this extracellular 
glutathione pool are warranted.  
Several mechanisms have been investigated to 
manipulate LLF glutathione content. Others are likely to 
follow as we learn to manipulate glutathione export and 
perhaps glutathionylation of LLF proteins [25]. One general 
strategy involves direct instillation of glutathione through the 
airway. Prousky has reviewed human trials utilizing this 
approach [26]. By and large this strategy produces modest 
increases in glutathione content. Side effects include 
increased GSSG content over GSH content and induction of 
bronchospasm [27, 28]. Bronchospasm may have resulted 
from sulfite sensitivity [26], or failure to neutralize the 
glutathione solution pH prior to instillation [29]. 
A second strategy involves modulating glutathione 
content with supplements of glutathione precursors, such as 
N-acetylcysteine, Procysteine or S-adenosylmethionine. 
These can be delivered directly through the airway or 
systemically. Oral delivery of these agents may have little 
direct impact on LLF glutathione [30, 31] but there value 
may still lie in the augmentation of cellular glutathione pools 
and increasing glutathione availability for export into LLF. 
Their effectiveness may only be evident when these 
glutathione pools are actually deficient [19, 20]. The 
membrane permeable precursor -glutamylcysteinylethyl 
ester has also been successfully used to supplement cellular 
glutathione content [32] and additional esterified precursors 
and glutathione itself are described in the literature [33]. 
A third strategy involves modulating glutathione 
metabolism by inhibiting GGT activity. This approach was 
based on our thorough characterization of GGT expression in 
normal lung, together with an animal model of GGT 
deficiency, the GGT
enu1 mouse [34-38]. We found that LLF 
GGT activity is: 1) associated with surfactant phospholipid, 
2) dynamic in nature, 3) directly accessible for 
pharmacologic manipulation and 4) a potent target for 
augmenting LLF glutathione content [3]. Limitation in 
cysteine supply induced by eliminating glutathione 
metabolism can be readily reversed with an external cysteine 
supplement.  
A fourth strategy involves delivery of aerosolized 
secretory leukoprotease inhibitor (SLPI). This protease 
inhibitor can increase LLF glutathione up to 5-fold and the 
effect lasts even at 24 hours after application [39]. This 
finding was totally unexpected and the mechanism of action 
remains unclear. However, SLPI does not inhibit GGT 
enzyme activity (R.P. Hughey and M. Joyce-Brady, 
unpublished observation) and this protease inhibitor could be 
explored for an additive effect on LLF glutathione 
augmentation when combined with inhibition of glutathione 
metabolism.  
GLUTATHIONE METABOLISM IN LLF  
Glutathione metabolism is regulated by GGT. The 
protein is synthesized as a monomer but the active enzyme is 
a heterodimer that is anchored to the external surface of the 
plasma membrane by its signal sequence [40]. It plays an 
essential role in the metabolism of extracellular glutathione 
and its S-conjugates by cleaving the -glutamyl amide bond. 
While the full physiological function of GGT is yet to be 
completely defined [41-43], as an ectoenzyme, it is believed 
to at least initiate the hydrolysis of extracellular glutathione 
to provide cells with secondary source of Cys, which is the 
rate-limiting substrate for de novo synthesis of intracellular 
glutathione [44, 45]. The enzyme is also present as a soluble 
form in extracellular biological fluids where it can function 
to distribute glutathione between cells and tissues [46].  
The GGT activity found in normal LLF is present in 
association with lung surfactant phospholipid. This soluble 
activity is derived, in part, as a secretory product of the 
alveolar type 2 (AT2) cell, and the amphipathic nature of 
GGT allows its redistribution throughout the entire surface 
of the lung along with surfactant [36]. The ontogeny of GGT 
in the AT2 cell during late fetal lung development parallels 
that of surfactant phospholipid so that LLF glutathione 
metabolism is active from the time of birth [37]. 
The GGT
enu1 mouse model of genetic GGT deficiency 
[34, 35] provided support for this biological role of 
glutathione metabolism in the lung. With limited cysteine 
availability, lung cells exhibited impaired glutathione 
synthesis, cellular glutathione deficiency, and oxidant stress 
in normoxia [47]. This was most evident in bronchiolar Clara 
cells, alveolar macrophages and vascular endothelial cells. In 
hyperoxia, cellular glutathione deficiency in the presence of 
this intracellular oxidant stressor, prediposed to excessive 
lung injury and accelerated mortality in GGT
enu1 mice [47, 
48]. Dietary supplements with the cysteine precursor N-
acetyl cysteine [48, 49] or L-2-oxothiazolidine-4-carboxylate 
[50] attenuated the cellular glutathione deficiency and lung 
sensitivity to hyperoxia [48]. 
However, glutathione content in the extracellular LLF 
pool of GGT
enu1 mice with genetic GGT deficiency was 
actually augmented in a fashion similar to that described in 
plasma [34, 49]. The increase in this glutathione pool 
strongly supported the concept that LLF glutathione 
undergoes turnover in the normal lung. The biological role of 
this LLF glutathione enhancement became evident when 
GGT
enu1 mice were exposed to an IL13-driven model of 
inflammatory airway disease [3]. Pro-inflammatory IL13 
treatment activated an extracellular burden of oxidant stress 
from the acute inflammatory response. In normal mice, there 
was little change in LLF fluid glutathione, GSH (Fig. 1 ). 
BAL LLF glutathione in GGT
enu1 mice started a 2-fold over 
normal baseline and increased 5-fold more after IL13, a level 
that was about 10-fold above the baseline level in normal 
mice.  
This surplus of LLF glutathione buffered extracellular 
reactive oxygen species derived from inflammatory cells and 
protected proteins in the LLF and the lung epithelial surface 
against oxidant stress, epithelial cells from mucin gene 
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induced in normal mice treated with IL13 but they could be 
partially attenuated by inhibiting their LLF GGT activity 
with the irreversible GGT inhibitor acivicin (Fig. 2 ). 
Interestingly, we found, as had others, that delivery of 
acivicin systemically had no effect on LLF GGT activity. To 
effectively inhibit this extracellular pool of enzyme activity 
and modulate LLF glutathione, acivicin had to be delivered 
through the airway [3].  
 
 
 
 
 
 
 
 
 
 
Fig. (1). LLF glutathione (GSH) and glutathione disulfide 
(GSSG) in normal (wild type, WT) and GGT
enu1 mice after 
saline (S) or IL13 treatment. LLF glutathione assessed as 
bronchoalveolar lavage fluid (BAL). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Loss of GGT activity augments LLF glutathione in 
presence of IL13. IL13, a pro-inflammatory cytokine, induces 
inflammation and an extracellular load of reactive oxygen species 
(ROS). These are buffered by the surplus of LLF glutathione in 
GGT deficient GGT
enu1 mice and injury is prevented. Normal mice 
are susceptible to injury and can be protected by inhibiting their 
LLF GGT with acivicin.  
INHIBITION OF GGT ENZYME ACTIVITY 
While several compounds are known to inhibit GGT 
enzyme activity, designing novel, potent and more selective 
inhibitors required a rational and mechanistic understanding 
of enzyme function. GGT-mediated glutathione hydrolysis 
occurs by a ping-pong mechanism [51-54] and utilizes a -
glutamyl ester intermediate (an acylenzyme) with an N-
terminal Thr residue in the small subunit (Thr391 [55] and 
Thr381 [56] of E. coli and human GGTs, respectively) as the 
catalytic nucleophile. The -glutamyl group is then 
transferred to water (hydrolysis) or to various amino acids 
and peptides (transpeptidation) if these acceptor molecules 
are present in high concentrations. Under physiological 
conditions, however, GGT is mainly regarded as the 
hydrolytic enzyme that initiates the release of Cys and other 
constituent amino acids from extracellular glutathione [44, 
45]. For in vitro and in vivo studies to probe the mechanisms 
and physiological functions of GGT, a number of inhibitors 
have been reported to date; the classical inhibitors of GGT 
include a serine-borate complex [57], a -boronate analog of 
glutamate (-boroGlu) [58, 59], anthglutin [60, 61] (Fig. 3) 
and several naturally occurring glutamine antagonists (Fig. 
4) [62-67].  
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Fig. (3). Classical inhibitors of GGT. These include: serine-borate 
complex, -boronate analog of glutamate and anthglutin.  
A serine-borate complex is a transition-state like adduct 
formed tentatively in the enzyme active site (Ki = 0.02 mM) 
and is readily dissociated when the enzyme is dialyzed [57]. 
Its boronate analog (-boroGlu) serves as a slow- and tight-
binding inhibitor with a substantial potency (Ki = 35 nM), 
but the inhibition is still reversible, and the inactivated 
enzyme regains activity rapidly [59]. Its development seems 
to have been terminated, and no further information is 
available regarding the properties of this compound such as 
the specificity and toxicity. Anthglutin was screened for 
GGT inhibitory activity from the culture medium of 
Penicillium oxalicum. Anthglutin is a naturally occurring 
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glutathione analog and serves as a competitive inhibitor for 
various GGTs with Ki values of 5-27 μM [60]. No acute 
toxicity was reported for mice (100 mg/kg of body weight). 
These classical inhibitors, however, are of limited use for in 
vivo inhibition of GGT in lung lining fluid, because they are 
rather weak or reversible so they do not suppress GGT 
activity for an appropriate period of time to exert therapeutic 
effects. 
In contrast, the naturally occurring glutamine antagonists 
such as acivicin [L-(S,5S)--amino-3-chloro-4,5-dihydro-
5-isoxazoleacetic acid, AT-125], L-DON (6-diazo-5-oxo-L-
norleucine) and azaserine (O-diazoacetyl-L-serine) are all 
chemically reactive and inhibit GGT irreversibly [62-67]. 
Among these glutamine antagonists, acivicin is by far the 
most popular inhibitor of GGT and has been used 
extensively not only for in vitro experiments [62-64], but 
also for in vivo studies to see the effect of chemical 
knockdown of GGT on tumor cells [68-71], bacterial 
pathogenicity [72], signal transduction in myocardial 
infarction [73], oxidative stress in pulmonary vascular 
endothelial cells [74] and xenobiotic metabolism in plants 
[75]. The main reason for the frequent use of acivicin is that 
this compound is commercially available (ex. Santa Cruz 
Biotechnology, Inc., USA; Haihang Industry Co., Ltd., 
China) and reacts readily with the catalytic Thr residue of 
GGT to form a covalent bond [76, 77]. No regain of enzyme 
activity was reported. Similarly, other glutamine antagonists 
such as L-DON and azaserine inhibit GGT in an irreversible 
manner, although the inactivation potency varies depending 
on the compound. From a pharmaceutical point of view, 
however, there is a critical problem associated with toxicity 
in using these compounds for the inactivation of GGT in 
vivo. Acivicin and the related glutamine antagonists are 
highly cytotoxic and inhibit a number of glutamine-
dependent biosynthetic enzymes [78, 79] such as glutamine 
PRPP amidotransferase, FGAR amidotransferase, IGP 
synthase, GMP synthetase and carbomoylphosphate 
synthetase involved in de novo purine and pyrimidine 
biosynthesis. Glucosamine 6-phosphate synthase, 
asparagines synthetase, NAD synthetase and anthranilate 
synthase are also inactivated by these compounds [80]. 
Acivicin is reported to have central nervous system (CNS) 
toxicity [81]. The toxic nature of acivicin and the related 
glutamine antagonists is based on a common mechanism: 
alkylation of the conserved and catalytically essential Cys 
residue of the glutaminase domain of the amidotransferases 
by the chemically reactive imino chloride (acivicin) [82-84] 
and diazoacyl groups (L-DON and azaserine) [79]. In this 
sense, these glutamine antagonists can be regarded as 
naturally occurring inhibitors of glutamine amidotransferases 
that liberate ammonia from glutamine for use as a nitrogen 
source of nucleotides, amino acids and amino sugars, but not 
per se as inhibitors of GGT. Therefore, the inactivation of 
GGT by acivicin, L-DON and azaserine is a fortuitous event 
that derives from the fact that GGT has a nucleophilic and 
catalytically essential Thr residue at the binding site near the 
-carboxy group of glutamine derivatives such as 
glutathione.  
In our effort to identify the catalytic residue of GGT, a -
monofluorophosphonate derivative of glutamate (Fig. 5 : 
compound 1) was synthesized. This compound served as a 
potent inactivator of E. coli GGT as a transition-state analog 
for successful affinity labeling the N-terminal Thr-391 in the 
small subunit as the catalytic nucleophile [55]. The 
fluorophosphonate (1), however, is chemically too reactive 
to be used as a general inhibitor of GGT. To attenuate the 
reactivity, a series of -(monophenyl)phosphono glutamate 
analogs were synthesized [85]. These compounds 
irreversibly inhibited E. coli and human GGTs with a 
reasonable rate and the inactivation rates toward the human 
enzyme surpassed that of acivicin when an electron-
withdrawing group was introduced (X = Ac, CN). In fact, 
compound 2 (X = CN in Fig. 5) was used successfully to 
identify the catalytic nucleophile of human GGT (the N-
terminal Thr-381 in the small subunit) [56]. In line with this 
study targeting the GGT catalytic nucleophile and the 
glutamate binding site, a series of -phosphono diester 
analogs of glutamate (3) were synthesized as second-
generation inhibitors [86]. Due to the increased 
electrophilicity of the phosphorus, these phosphonate 
diesters are 20 to 40-fold more active than the corresponding 
monoesters (2). To our surprise, the umbelliferone derivative 
(4) exhibited an extraordinarily high activity toward the 
human enzyme with the inactivation rate reaching 6000 
times that of acivicin. This finding has led to design the 
third-generation inhibitors (5 and 6) which mimic the 
structure of glutathione and its C-terminal carboxy group to 
interact with the active site of the human enzyme. In 
particular, compound 6 with a simplified Cys-Gly moiety (a 
phenyl ring) and a carboxymethyl group at the meta position 
is highly promising in that it compromises chemical stability 
and high activity toward the human enzyme. In fact, 
compound 6 is reasonably stable (3% hydrolysis in neutral 
water for 1 month at 25°C) and inhibited human GGT with 
an inactivation rate more than 120 times higher than that of 
acivicin. No regain of enzyme activity was observed. 
Interestingly, the para-substituted analog (7) was 155-times 
less active than compound 6, indicating that the human 
enzyme strictly recognizes the meta-carboxy group that is 
equivalent to the C-terminal carboxy group of 
glutathione[86]. Furthermore compound 6 does not inhibit 
glutamine-dependent asparagines synthetase, has no toxicity 
toward human fibroblasts up to 10 mM and has passed the 
GLP safety guidelines (unpublished results). Therefore, 
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compound  6 is so far the most promising candidate for 
pharmaceuticals to chemically inactivate GGT activity in 
vivo. This compound does inhibit lung GGT activity, but like 
acivicin, our preliminary data shows that it must be delivered 
through the airway (Joyce-Brady and Hiratake, unpublished 
observation). Hence the advantages of compound 6 include: 
specificity, potency, and lack of toxicity. Compound 6 is 
now commercially available under the name of GGsTop 
from Wako Pure Chemical Industries, Ltd., Japan. 
Other synthetic GGT inhibitors reported to date include a 
series of L-homocysteine analogs (sulfides, sulfoxides, 
sulfones and sulfoximines) [87, 88]. A sulfoxide analog with 
a Cys-Gly moiety exhibited the highest activity (Ki = 53 μM, 
competitive with respect to -glutamyl 4-nitroanilide) toward 
rat kidney GGT, highlighting the importance of the binding 
of the Cys-Gly moiety of glutathione with mammalian GGT. 
S
N
H
O O
S
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N
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Fig. (6). Chemical structure OU749. 
Recently, Hanigan et al. reported a high-throughput 
screening approach to find a drug-like, non-glutamate analog 
OU749 and its derivatives as inhibitors of human GGT [89]. 
From kinetic studies, this compound was found to occupy 
the acceptor site of the -glutamyl substrate complex with a 
Ki of 17.6 μM. The inhibition is species-specific and is 
reported to inhibit human kidney GGT with 7- to 10-times 
potency than those from rat or mouse kidney. Despite the 
fact that these compounds target the acceptor-site of GGT, 
toxicity is still reported. Optimal activity also requires a high 
level of GGT enzyme activity which is not the case in the 
lung [36]. 
CONCLUSIONS 
LLF is composed of a highly concentrated pool of 
glutathione that serves a biological role in antioxidant 
defense and cysteine supply over the entire lung surface. 
This extracellular glutathione pool is dynamic and reduced 
glutathione predominates. That LLF glutathione content is 
related to the level of oxidant burden at the lung epithelial 
surface has been recapitulated in studies over time. Ongoing 
efforts to assess and manipulate this pool to protect against 
extracellular oxidant stress are warranted and novel 
mechanisms to accomplish this goal are available. Studies 
suggest that early identification and correction of LLF 
glutathione deficiency can prevent lung injury and disease. 
Glutathione metabolism plays a role in determining the size 
of the LLF glutathione pool. Induction of GGT activity with 
the onset of acute lung injury and inflammation contributes 
to a relative deficiency of LLF glutathione, even in children 
with cystic fibrosis [90]. Inhibiting this metabolism by 
targeting active GGT enzyme can bolster LLF glutathione 
content and augment antioxidant defense at the lung surface. 
It is remarkable that targeting of a single antioxidant enzyme 
in LLF can be protective even in the presence of a high 
inflammatory load [3]. Nonetheless, oxidizing events 
originating within the LLF have recently been proposed as 
the unifying mechanism that initiates syndromes of acute 
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Fig. (5). Novel, potent -phosphono diseter analogs of glutamate. Each compound is referred to by number in the text. 76    Current Enzyme Inhibition, 2011, Vol. 7, No. 2  Joyce-Brady and Hiratake 
lung injury [2] and cytokine-driven asthma [3]. Since LLF 
proteins are directly accessible to pharmacologic 
interventions, focused assessment and specific manipulation 
of LLF glutathione to enhance extracellular antioxidant 
defense may yet prove to be a viable strategy to prevent and 
alleviate oxidant-mediated lung injury.  
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ABBREVIATIONS 
GGT =  -glutamyl transferase 
GSH =  Glutathione 
GSSG =  Glutathione  disulfide 
SLPI =  Secretory  leukoprotease  inhibitor 
GGT
enu1 =  -glutamyl transferase deficient mouse 
mutated with ethylnitrosourea 
BAL =  Bronchoalveolar  lavage 
Thr =  Threonine 
DON =  6-diazo-5-oxo-L-norleucine 
PRPP =  Phosphoribosylpyrophosphate 
FGAR = 5-phosphoribosyl-N-formylglycinamide 
IGP  =  Imidazole glycerol phosphate 
GMP =  Guanine  monophosphate 
NAD =  Nicotinamide  adenine  dinucleotide 
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